Links

Tools

Export citation

Search in Google Scholar

A phase I Study of 177 Lu-DOTA-HH1 (Betalutin™) Radioimmunotherapy in Patients with Relapsed CD37 + Non-Hodgkin B-Cell Lymphoma

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

The CD37 antigen is expressed by majority of B-lymphoid malignancies and represents a promising therapeutic target for the treatment of B-cell non-Hodgkin Lymphoma (NHL). • 177 Lu-DOTA-HH1 (Betalutin™) is a novel anti-CD37 radioimmunoconjugate currently under clinical development 1. • Betalutin™ consists of the β-emitting isotope Lutetium-177 (T 1/2 =6.7 days) chelated to the chemical linker DOTA conjugated to the murine mAb HH1 2. • Data from an ongoing first in man phase I/II study (Lymrit-37-01), evaluating Betalutin™ in patients with relapsed CD37 + NHL are presented.